For Newer Sepsis Diagnostics, What the Studies Show

Why It Matters

Accurate early sepsis detection can accelerate treatment pathways, reduce mortality, and improve hospital workflow, making the validation and integration of these novel diagnostics a critical priority for emergency and laboratory medicine.

Summary

Newer sepsis diagnostics such as monocyte distribution width (MDW), Intellisep, and MeMed BV are showing promise in early clinical studies but each has distinct limitations. MDW, available on the Beckman Coulter CBC platform, improves sepsis detection when combined with white‑blood‑cell count but suffers from modest sensitivity and specificity. Intellisep offers good sensitivity and specificity and potential prognostic value but requires a dedicated instrument and physician interpretation. Despite these advances, institutions like Barnes‑Jewish Hospital are not yet adopting any of these assays, citing the heterogeneous nature of sepsis and the need for multiple biomarkers to cover its varied phenotypes.